Mechanism of action
Secobarbital acts primarily on the GABA-A receptor complex, the major inhibitory neurotransmitter system in the central nervous system. Unlike benzodiazepines, which increase the frequency of chloride channel opening, barbiturates like secobarbital prolong the duration of chloride channel opening. At higher concentrations, secobarbital can directly activate GABA-A receptors even in the absence of GABA, explaining its greater toxicity compared to benzodiazepines.
The enhanced chloride influx hyperpolarizes neuronal membranes, reducing neuronal excitability throughout the CNS. This produces dose-dependent effects ranging from sedation and hypnosis to anesthesia and coma. Secobarbital also depresses the reticular activating system, which regulates arousal and consciousness.
At supratherapeutic doses, secobarbital inhibits excitatory neurotransmission by blocking AMPA-type glutamate receptors and reducing calcium influx through voltage-gated calcium channels. These effects contribute to its anticonvulsant properties but also increase the risk of fatal overdose, as barbiturates lack a ceiling effect for respiratory depression.
- Secobarbital prolongs chloride channel opening at GABA-A receptors, unlike benzodiazepines which increase opening frequency
- Schedule II controlled substance with high abuse potential and rapid development of tolerance and physical dependence
- Potent CYP450 inducer: reduces efficacy of oral contraceptives, warfarin, and many other drugs after 1-2 weeks of use
- No ceiling effect for respiratory depression; overdose is life-threatening and lacks a specific antidote
- Barbiturate withdrawal syndrome is more severe than benzodiazepine withdrawal and can cause seizures and death
- Absolutely contraindicated in acute intermittent porphyria due to induction of ALA synthase
- Paradoxical excitation may occur in children and elderly instead of expected sedation
- Highly lipophilic with extensive hepatic metabolism; less than 5% excreted unchanged in urine
Indications
Secobarbital has very limited modern clinical indications due to safer alternatives and significant abuse potential:
- Insomnia (short-term): Reserved for refractory cases unresponsive to other agents, typically for fewer than 2 weeks due to rapid tolerance development
- Preoperative sedation: Occasionally used for anxiolysis before procedures, though benzodiazepines are now preferred
- Refractory status epilepticus: In intensive care settings when other anticonvulsants have failed
- Euthanasia protocols: Used in jurisdictions permitting medical aid in dying
Historically, secobarbital was widely prescribed for anxiety and sleep disorders, but the introduction of benzodiazepines in the 1960s and non-benzodiazepine hypnotics in the 1990s dramatically reduced its use. It remains a Schedule II controlled substance in the United States due to high abuse and dependence potential.
Pharmacokinetics
Secobarbital is classified as a short-acting barbiturate with rapid onset and relatively brief duration of action.
Absorption: Well absorbed orally with onset of action in 15-30 minutes. Peak plasma concentrations occur within 1-4 hours.
Distribution: Highly lipophilic, leading to rapid distribution into the CNS and other tissues. Approximately 30-45% protein-bound in plasma. Crosses the placenta and enters breast milk.
Metabolism: Extensively metabolized in the liver via oxidation and conjugation. Secobarbital is a potent inducer of cytochrome P450 enzymes, particularly CYP2C9, CYP2C19, and CYP3A4. This enzyme induction develops over 1-2 weeks of therapy and can persist for weeks after discontinuation.
Elimination: Metabolites are excreted primarily in urine. The elimination half-life is approximately 15-40 hours, though this is prolonged in hepatic impairment and elderly patients. Less than 5% is excreted unchanged in urine.
The short duration of clinical effect (3-4 hours for hypnosis) reflects redistribution from the CNS to peripheral tissues rather than true elimination, a characteristic shared with other lipophilic CNS depressants.
Adverse effects
Secobarbital carries significant risks, particularly with chronic use or overdose:
Central Nervous System
- Respiratory depression: Dose-dependent and potentially fatal, especially when combined with other CNS depressants
- Sedation, drowsiness, and cognitive impairment
- Paradoxical excitement or confusion, particularly in elderly patients or children
- Ataxia and impaired coordination
- Hangover effect with morning grogginess
Tolerance and Dependence
- Physical dependence develops rapidly, often within 2 weeks of regular use
- Tolerance to sedative effects occurs faster than tolerance to respiratory depression, increasing overdose risk
- Withdrawal syndrome can be life-threatening, characterized by anxiety, tremor, insomnia, seizures, and delirium; withdrawal severity exceeds that of benzodiazepines
Cardiovascular
- Hypotension due to peripheral vasodilation and myocardial depression
- Bradycardia at toxic doses
Hypersensitivity
- Rash, including Stevens-Johnson syndrome (rare)
- Angioedema
Other
- Hepatotoxicity with prolonged use
- Blood dyscrasias (rare): megaloblastic anemia, agranulocytosis
- Osteomalacia with chronic therapy due to increased vitamin D metabolism
Overdose presents with progressive CNS and respiratory depression, hypothermia, hypotension, and coma. There is no specific antidote; management is supportive with airway protection, mechanical ventilation, and hemodynamic support.
Contraindications and warnings
Absolute Contraindications
- Hypersensitivity to barbiturates
- Severe respiratory insufficiency or sleep apnea
- Acute intermittent porphyria (barbiturates induce ALA synthase, precipitating attacks)
- Severe hepatic impairment
Relative Contraindications and Warnings
- Pregnancy: Category D. Barbiturates cross the placenta and are associated with fetal harm, including congenital malformations and neonatal withdrawal syndrome. Use only if potential benefit justifies fetal risk.
- Breastfeeding: Excreted in breast milk; may cause sedation and withdrawal in infants
- Elderly patients: Increased sensitivity to CNS depression and paradoxical reactions
- Renal impairment: Metabolites accumulate; dose reduction advised
- History of substance abuse: High potential for misuse and diversion
- Depression or suicidal ideation: Risk of intentional overdose
- Driving and operating machinery: Impairs cognitive and motor function; advise patients to avoid these activities
Black Box Warnings
While secobarbital does not carry a formal FDA black box warning, it shares the general barbiturate risks of fatal respiratory depression, particularly when combined with opioids, alcohol, or benzodiazepines, and severe or fatal withdrawal reactions upon abrupt discontinuation.
Drug interactions
Secobarbital has extensive drug interactions due to its CNS depressant effects and potent enzyme induction:
CNS Depressants (Increased sedation and respiratory depression)
- Alcohol
- Opioid analgesics
- Benzodiazepines
- Other sedative-hypnotics
- Antipsychotics
- First-generation antihistamines
CYP450 Enzyme Induction (Reduced efficacy of substrates)
Secobarbital induces CYP2C9, CYP2C19, and CYP3A4, decreasing plasma concentrations of:
- Oral contraceptives: Increased risk of contraceptive failure; alternative contraception recommended
- Warfarin: Reduced anticoagulant effect
- Corticosteroids: Decreased immunosuppressive and anti-inflammatory effects
- Antiretrovirals (protease inhibitors, NNRTIs): Reduced antiviral efficacy
- Cyclosporine and tacrolimus: Risk of transplant rejection
- Thyroid hormones: May require dose adjustment
- Phenytoin: Complex bidirectional interaction
- Theophylline: Reduced bronchodilator effect
- Metronidazole: Decreased antimicrobial efficacy
Drugs Affecting Secobarbital
- MAO inhibitors: Prolong barbiturate effects
- Valproic acid: Inhibits secobarbital metabolism, increasing toxicity risk
- Rifampin: Induces secobarbital metabolism, reducing efficacy
Other Interactions
- Vitamin K antagonists: Enhanced metabolism reduces anticoagulation
- Griseofulvin: Reduced antifungal effect due to malabsorption
- Doxycycline: Shortened half-life; consider alternative antibiotic
Patients should avoid alcohol completely while taking secobarbital. Clinicians must review all concomitant medications before prescribing and counsel patients about enzyme induction effects that may persist for weeks after discontinuation.
Clinical pearls
- Barbiturate withdrawal is life-threatening and more dangerous than benzodiazepine or opioid withdrawal. Abrupt discontinuation after chronic use can precipitate seizures and delirium. Taper slowly over weeks to months with phenobarbital substitution if needed.
- No ceiling effect for respiratory depression: Unlike benzodiazepines, barbiturates can cause fatal respiratory arrest even in monotherapy overdose. This fundamental difference makes them far more dangerous.
- Enzyme induction takes 1-2 weeks to develop and persists for a similar duration after discontinuation. Warn patients using oral contraceptives about pregnancy risk, and monitor anticoagulation closely in patients on warfarin.
- Paradoxical excitation may occur, especially in children, elderly patients, or those with pain. This presents as agitation, confusion, or aggression rather than expected sedation.
- Porphyria screen before initiating therapy in patients with family history or unexplained abdominal pain, as barbiturates are absolutely contraindicated in acute intermittent porphyria.
- Cross-tolerance exists between barbiturates, benzodiazepines, and alcohol. Patients tolerant to one class may require higher doses of another for clinical effect.
- Schedule II status requires special prescribing procedures in the United States, including written prescriptions (in most states) and limited refills, reflecting high abuse potential.
- Safer alternatives exist for nearly all indications: benzodiazepines, Z-drugs (zolpidem, eszopiclone), and newer agents like suvorexant offer better safety profiles for insomnia. Reserve secobarbital for truly refractory cases.
- In exam questions, look for enzyme induction interactions (contraceptive failure, warfarin resistance) and life-threatening withdrawal as classic testable scenarios. The combination with alcohol or opioids leading to respiratory arrest is another high-yield pattern.
BARBITURATES mechanism: Bind GABA-A, Augment chloride, Respiratory depression (no ceiling), Bad withdrawal (seizures), Induce P450 enzymes, Tolerance rapid, Used rarely now, Rapid redistribution from CNS, Acute intermittent porphyria contraindication, Toxic in overdose, Elimination half-life 15-40 hours, Schedule II controlled substance
Practice questions
1. A 62-year-old man with chronic insomnia has been taking secobarbital 100 mg nightly for the past 6 weeks after failing multiple other sleep aids. He presents to the emergency department 48 hours after abruptly stopping the medication with tremors, anxiety, visual hallucinations, and tonic-clonic seizure activity. His vital signs show blood pressure 168/102 mmHg, heart rate 118 bpm, and temperature 38.1°C. Which of the following is the most appropriate immediate management?
2. A 28-year-old woman taking secobarbital for refractory insomnia comes to the clinic requesting a refill. She mentions that she recently started oral contraceptive pills prescribed by her gynecologist for cycle regulation. On physical examination, she appears well. Which of the following best explains the mechanism by which secobarbital affects her contraceptive efficacy?
3. A 45-year-old man is brought to the emergency department unresponsive after a suspected overdose. Empty bottles of secobarbital and alcohol are found at the scene. On examination, he has minimal respiratory effort with oxygen saturation of 76% on room air, blood pressure 78/45 mmHg, and absent deep tendon reflexes. After securing the airway and initiating mechanical ventilation, which of the following is the most appropriate next step in management?
Frequently asked questions
How does secobarbital work?
Secobarbital enhances the activity of GABA-A receptors by prolonging the duration of chloride channel opening, which hyperpolarizes neurons and reduces excitability throughout the central nervous system. At higher doses, it can directly activate GABA-A receptors without GABA present, explaining its potential for fatal respiratory depression. This mechanism differs from benzodiazepines, which increase the frequency rather than duration of channel opening, giving benzodiazepines a safer profile with a ceiling effect for respiratory depression.
What are the side effects of secobarbital?
The most serious side effect is dose-dependent respiratory depression, which can be fatal, especially when combined with alcohol, opioids, or other CNS depressants. Other common effects include sedation, drowsiness, cognitive impairment, ataxia, and hangover effects. Chronic use rapidly leads to physical dependence and tolerance, with withdrawal syndrome potentially causing life-threatening seizures and delirium. Paradoxical excitation, hypotension, and rare hypersensitivity reactions can also occur.
Is secobarbital a controlled substance?
Yes, secobarbital is a Schedule II controlled substance in the United States, reflecting its high potential for abuse and severe physical and psychological dependence. This classification requires special prescribing procedures, including written prescriptions in most jurisdictions and limitations on refills. The drug's abuse potential, combined with its narrow therapeutic index and availability of safer alternatives, has dramatically reduced its clinical use since the 1960s.
Can you take secobarbital with alcohol?
No, alcohol should never be combined with secobarbital. Both are CNS depressants that have additive or synergistic effects on respiratory depression, potentially leading to fatal respiratory arrest. This combination also significantly increases the risk of severe sedation, loss of consciousness, hypotension, and aspiration. Patients must be explicitly warned to avoid all alcohol consumption while taking secobarbital and for several days after discontinuation.
Secobarbital vs phenobarbital — what is the difference?
Secobarbital is a short-acting barbiturate with rapid onset (15-30 minutes) and duration of 3-4 hours, historically used for insomnia and procedural sedation. Phenobarbital is a long-acting barbiturate with slower onset and duration of 10-12 hours, primarily used for seizure disorders and barbiturate withdrawal management. Secobarbital is Schedule II due to higher abuse potential, while phenobarbital is Schedule IV. Both induce hepatic enzymes, but phenobarbital's longer half-life (50-120 hours) makes it preferable for controlled tapering during barbiturate dependence treatment.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N05CA06
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.